Dr. Colowick has served on our board of directors since May 2019. Since May 2017, Dr. Colowick has served as a Partner at Sofinnova Investment, Inc., a clinical stage life sciences venture capital firm. From February 2010 to April 2017, Dr. Colowick held various positions, including Executive Vice President, at Celgene Corporation, a pharmaceutical company. [...]
Mr. Ricci has served on our board of directors since February 2019. Since October 2018, Mr. Ricci has served as an Advisor to Lightspeed Venture Partners, an early-stage technology venture capital firm. Since September 2018, Mr. Ricci has served as an Advisor to Warburg Pincus, a private equity firm. Mr. Ricci served as Chief Executive Officer of Nuance Communications, [...]
Mr. Bowman has served on our board of directors since May 2019. Beginning in 2006, Mr. Bowman served on the board of directors of Solexa, Inc., a DNA sequencing company, until its sale to Illumina, Inc., a biotechnology company, after which Mr. Bowman continued to serve on the board of directors until May 2018. From March 1977 to August 2005, [...]
When an Exome Test Is Part of the Therapy and Not a Diagnostic: John West on Personalis and Personalized Cancer Vaccines John West, CEO, Personalis John West discusses how Personalis is participating in the dramatic shift in drug development toward immuno-oncology drugs. Go to podcast [...]
ImmunogenomicsID™ Comprehensive immunogenomic characterization ImmunogenomicsID™, the latest analytics component of the ACE ImmunoID platform, summarizes critical areas of tumor biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, and tumor escape. ImmunogenomicsID combines exome and transcriptome sequencing data from a paired tumor and normal [...]
Personalis, Inc. Launches Early Access Program for Cell-Free DNA ACE Exome for Tumor Neoantigens Menlo Park, CA – November 16, 2017 – Personalis, Inc., today announced the launch of an Early Access Program for its cell-free DNA (cfDNA) technology, which enables the detection of neoantigens across an exome (~20,000 genes) from a single [...]
The Fight Against Cancer: Neoantigens, Tumor Escape and the Tumor Microenvironment A conversation with JOHN WEST, CEO of Personalis, Inc. in Menlo, Park, California Nature, October 26, 2017 Tumours may be initiated by mutations in their driver genes, but their clinical outcomes are strongly influenced by the battle between [...]
Getting cancer vaccines right: Key challenges and solutions for neoantigen identification A conversation with Richard Chen, MD, CSO of Personalis, Inc. in Menlo, Park, California FierceBiotech, June 26, 2017 The promise of neoantigen-based cancer vaccines Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer. The development [...]
We use machine learning and neural networks to provide you with advanced analytics to better inform your discovery and translational research programs. Leveraging our enhanced exome and transcriptome, we’ve applied these assays for deeper bioinformatics analysis to accurately predict neoantigens. Using neoantigens as a predictor for determining likelihood of response to immunotherapies is one exciting [...]
Many clinical studies depend on tissue archives that have been fixed using FFPE procedures. This preservation process makes it difficult to obtain a pure sample and often leads to RNA degradation. To overcome this challenge, Personalis has developed an exome-capture transcriptome protocol based on our ACE Technology that allows us to produce high-quality transcriptome sequencing [...]
